KKR completed its $5.89 billion acquisition of Integer Holdings on August 29, securing the largest healthcare PE transaction of the quarter as global buyout activity collapsed to levels not seen since Q1 2021. The medical-device manufacturer, which supplies cardiac rhythm management systems and neuromodulation components to Medtronic and Abbott, exits public markets at $104.50 per share—a 41% premium to its six-month average before acquisition rumors surfaced in June.
August recorded $22.7 billion in announced global PE deals, down 68% from the twelve-month rolling average and the thinnest monthly volume since March 2021. Healthcare accounted for $8.1 billion of that total. KKR's Integer take-private represented 26% of all PE capital deployed globally during the month. The firm funded the transaction with $2.3 billion in equity from its Americas XII and Next Generation Technology Growth Fund II vehicles, alongside $3.6 billion in leveraged debt arranged by Morgan Stanley and JPMorgan at a blended cost of 6.8%—tight for a non-investment-grade medical issuer in the current rate environment.
The deal matters because it establishes a valuation ceiling for scaled contract manufacturers in the medical-device supply chain at roughly 14.2x forward EBITDA, a multiple that had been theoretical until this print. Integer generated $1.49 billion in trailing revenue with 28.3% EBITDA margins, cleaner than publicly traded peers averaging 23-25%. KKR identified $140 million in annual run-rate synergies by 2028 through procurement consolidation and shifting 37% of production to lower-cost geographies, primarily Malaysia and Costa Rica. The firm also plans to collapse Integer's portfolio from 14 product families to 9, exiting lower-margin peripheral vascular lines that contributed $187 million in revenue but only 16% EBITDA margins.
This acquisition reshapes the private-equity healthcare landscape in two ways. First, it signals that mega-funds are willing to pay north of 14x for scaled, sole-source suppliers with sticky customer relationships—Integer holds 67% wallet share with its top five OEM customers under contracts averaging 8.4 years remaining. Second, it confirms that the medical-device supply chain, not branded devices themselves, offers the delta large funds need. Integer's gross margins expanded 290 basis points in the two years preceding the deal, even as end-market device companies faced pricing pressure from hospital systems. The margin expansion came from design-for-manufacturability partnerships that locked Integer into early-stage product development with customers, creating switching costs that public investors undervalued.
Operators should track three follow-on events. First, whether KKR refinances the $1.2 billion 2029 maturity tranche by Q1 2026 to extend the runway before any margin compression from the manufacturing shift materializes. Second, watch for Integer's two largest competitors—Greatbatch Medical (already PE-owned by Madison Dearborn) and Nortech Systems—to test sale processes by mid-2025. Third, monitor KKR's $890 million co-investment from the Abu Dhabi Investment Authority, which took 15% of the equity; ADIA has co-anchored only four deals above $5 billion in the past thirty-six months, suggesting sovereign LPs see durable yield in this subsector.
Integer's Plano and Tijuana facilities are already operating under KKR ownership, with the first $40 million tranche of capex approved for cleanroom expansion in Malaysia, scheduled for commissioning in Q3 2026.